arrow
G

Girish S. Kulkarni

University of Toronto
H指数:50
被引数:9,212

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IS THE DIGITAL RECTAL EXAM (DRE) STILL RELEVANT IN THE ERA OF MRI IMAGING? RESULTS OF AN INTERNATIONAL MULTI-INSTITUTIONAL STUDY

数字直肠检查(DRE)在MRI成像时代是否仍然相关?国际多机构研究的结果

2026-05-010
PRE
E-XQR-30: evidence for an increase in the ionization state of metal absorbers from z ∼ 6 to z ∼ 2

E-XQR-30:关于金属吸收体电离态从z∼6到z∼2增加的证据

2026-02-010
OA
Comparison of 90-day morbidity and mortality between ileal conduit and orthotopic neobladder following radical cystectomy in a large, multi-institutional database The Canadian CBCis experience

在大型多机构数据库中比较根治性膀胱切除术后回肠导管和原位新膀胱的90天发病率和死亡率:加拿大CBCis研究经验

2026-01-010
PRE
A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada

一项基于人群的分析,研究加拿大艾伯塔省新发肌层浸润性膀胱癌患者的治疗模式。

2025-12-010
PRE
Analysis of upper tract urothelial carcinoma in the Asian population

亚洲人群中上尿路尿路上皮癌的分析

2025-12-010
PRE
Effect of Sex Differences on Cancer Outcomes After Chemo-Radiation for Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort Study

性差异对肌肉浸润性膀胱癌化疗放疗后癌症结局的影响:一项回顾性多中心队列研究

2025-11-010
PRE
Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer

非肌层浸润性膀胱癌治疗后上尿路移行细胞癌的发病风险

2025-11-010
OAAI
Development and International Evaluation of an Artificial Intelligence–based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non–muscle-invasive Bladder Cancer

基于人工智能的模型(PROGRxN-BCa)的开发与国际评估:使用世界卫生组织2004/2022分级系统预测进展风险并改善非肌层浸润性膀胱癌的亚分层

2025-10-070
PRE
A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada

来自加拿大阿尔伯塔省的高风险非肌层浸润性膀胱癌患者护理模式的人口基础分析

2025-10-011
OAAI
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study

患者和医师特征与雄激素剥夺疗法强化治疗在去势敏感型转移性前列腺癌初诊患者中的关联:一项基于人群的研究

Cancer
IF5.1
2025-09-040
OAAI
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

作者更正: Sasanlimab加BCG在BCG幼稚,高危非肌层浸润性膀胱癌中的应用: 随机3期CREST试验

2025-07-210
OA
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk

合并原位癌分布对非肌层浸润性膀胱癌进展风险的影响

2025-05-260
OAAI
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC

地平线上的视野:关于为BCG-Naïve高危非肌层浸润性膀胱癌患者提供新兴疗法的全球多学科观点

2025-04-170
OA
Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer
2025-02-010
OAAI
Tranexamic Acid During Radical Cystectomy A Randomized Clinical Trial

氨甲环酸在根治性膀胱切除术中的应用随机临床试验

2024-12-011
PRE
Proportion of Gleason Score‡8 Prostate Cancer on Biopsyand Tumor Aggressiveness in Matched Cohorts ofEast Asian and Non-East Asian Men

活检中 Gleason Score‡8 前列腺癌的比例及东亚和非东亚男性匹配队列中的肿瘤侵袭性

2024-12-011
OA